Literature DB >> 10323318

Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure.

G Hageman1, J van der Hoek, M van Hout, G van der Laan, E J Steur, W de Bruin, K Herholz.   

Abstract

It is well known that exposure to manganese, solvents, or carbon monoxide in an occupational setting may lead to central nervous system damage and parkinsonism. The most important solvents in this respect are methanol, toluene, carbon disulfide, and n-hexane. We describe three patients who had been exposed to various solvents for more than 20 years (25, 34, and 46 years). They presented with parkinsonism, pyramidal signs, mild cognitive decline, and unresponsiveness to levodopa. Two patients had a predominantly axonal and sensory polyneuropathy of the lower legs with fasciculations in one of them. Parkinsonian features were progressive, even after the patients had stopped work. We present clinical data, neuropsychological findings, and results of brain computed tomography or magnetic resonance imaging, electroneuromyography, evoked potentials, single photon emission computed tomography, and positron-emission tomography. There is growing evidence that various organic solvents give rise to a parkinsonism syndrome with pyramidal features in susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323318     DOI: 10.1007/s004150050334

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

Review 1.  The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

Review 2.  Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration.

Authors:  Blanca A Silva; Leonid Breydo; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-09-01       Impact factor: 5.590

Review 3.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

4.  Effect of pesticides on the aggregation of mutant huntingtin protein.

Authors:  Ruhi S Deshmukh; Rajeev K Chaudhary; Ipsita Roy
Journal:  Mol Neurobiol       Date:  2012-03-14       Impact factor: 5.590

5.  Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10.

Authors:  Mallika Somayajulu-Niţu; Jagdeep K Sandhu; Jerome Cohen; Marianna Sikorska; T S Sridhar; Anca Matei; Henryk Borowy-Borowski; Siyaram Pandey
Journal:  BMC Neurosci       Date:  2009-07-27       Impact factor: 3.288

6.  A highly reproducible rotenone model of Parkinson's disease.

Authors:  Jason R Cannon; Victor Tapias; Hye Mee Na; Anthony S Honick; Robert E Drolet; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

7.  Genetic susceptibility in solvent induced neurobehavioral effects.

Authors:  L Godderis; N Maertens; V de Gelder; A De Lamper; K De Ruyck; M Vernimmen; S Bulterys; G Moens; H Thierens; M K Viaene
Journal:  Neurotox Res       Date:  2009-08-22       Impact factor: 3.911

Review 8.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.

Authors:  Vladimir N Uversky; David Eliezer
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

9.  Neuromuscular Functions on Experimental Acute Methanol Intoxication.

Authors:  Ali Reşat Moral; İlkin Çankayalı; Demet Sergin; Özden Boyacılar
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-08-21

10.  Cognitive functioning in patients with suspected chronic toxic encephalopathy: evidence for neuropsychological disturbances after controlling for insufficient effort.

Authors:  M S E van Hout; B Schmand; E M Wekking; B G Deelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.